دورية أكاديمية
Next-Generation Sequencing in Clinical Practice. Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?
| العنوان: | Next-Generation Sequencing in Clinical Practice. Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? |
|---|---|
| المؤلفون: | Pruneri G., De Braud F., Sapino A., Aglietta M., Vecchione A., Giusti R., Marchio C., Scarpino S., Baggi A., Bonetti G., Franzini J. M., Volpe M., Jommi C. |
| المساهمون: | Pruneri, G., De Braud, F., Sapino, A., Aglietta, M., Vecchione, A., Giusti, R., Marchio, C., Scarpino, S., Baggi, A., Bonetti, G., Franzini, J. M., Volpe, M., Jommi, C. |
| بيانات النشر: | Adis |
| سنة النشر: | 2021 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: | ng, pharmacogenomic, precison medicine |
| الوصف: | Objectives: This study aimed to compare the costs of a next-generation sequencing-based (NGS-based) panel testing strategy to those of a single-gene testing-based (SGT-based) strategy, considering different scenarios of clinical practice evolution. Methods: Three Italian hospitals were analysed, and four different testing pathways (paths 1, 2, 3, and 4) were identified: two for advanced non-small-cell lung cancer (aNSCLC) patients and two for unresectable metastatic colon-rectal cancer (mCRC) patients. For each path, we explored four scenarios considering the current clinical practice and its expected evolution. The 16 testing cases (4 scenarios × 4 paths) were then compared in terms of differential costs between the NGS-based and SGT-based approaches considering personnel, consumables, equipment, and overhead costs. Break-even and sensitivity analyses were performed. Data gathering, aimed at identifying the hospital setup, was performed through a semi-structured questionnaire administered to the professionals involved in testing activities. Results: The NGS-based strategy was found to be a cost-saving alternative to the SGT-based strategy in 15 of the 16 testing cases. The break-even threshold, the minimum number of patients required to make the NGS-based approach less costly than the SGT-based approach, varied across the testing cases depending on molecular alterations tested, techniques adopted, and specific costs. The analysis found the NGS-based approach to be less costly than the SGT-based approach in nine of the 16 testing cases at any volume of tests performed; in six cases, the NGS-based approach was found to be less costly above a threshold (and in one case, it was found to be always more expensive). Savings obtained using an NGS-based approach ranged from €30 to €1249 per patient; in the unique testing case where NGS was more costly, the additional cost per patient was €25. Conclusions: An NGS-based approach may be less costly than an SGT-based approach; also, generated savings increase with the ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/33660227; info:eu-repo/semantics/altIdentifier/wos/WOS:000625044400001; issue:Mar 4; firstpage:1; lastpage:14; numberofpages:14; journal:PHARMACOECONOMICS-OPEN; http://hdl.handle.net/11573/1521675Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85102032193 |
| DOI: | 10.1007/s41669-020-00249-0 |
| الإتاحة: | https://doi.org/10.1007/s41669-020-00249-0Test http://hdl.handle.net/11573/1521675Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.6B9B786C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s41669-020-00249-0 |
|---|